 |
|
|
|
This month we would like to know...
How frequently do you access The Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Centers (EPCs)?
| a) |
Frequently |
| |
|
| b) |
Rarely |
| |
|
| c) |
Never |
| |
|
Vote in our survey, and see what other P&T committee members have to say.
 |
|
|
Contact Us
Click here to contact a Formulary editor.
Click here to contact a Formulary sales representative.
Click here to learn about direct mail, reprints and classifieds in Formulary. |
|
|
|
FEBRUARY 12, 2010 |
Confirm your subscription click here.
In order to ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Drugs for orphan diseases seeing more FDA approvals
Federal regulatory agencies are signing off on more new product approvals for treatment of so-called neglected diseases in recent years. One reason for the rise in approvals may be tied to increased research and development (R&D) funding available, report researchers at the Tufts Center for the Study of Drug Development (CSDD) in the November/December Tufts CSDD Impact Report. More... |
|
Two new antiplatelet agents go head to head with clopidogrel in the setting of PCI
Two investigational competitors to clopidogrel took their shots against the antiplatelet giant in 3 separate randomized controlled phase 3 trials of patients undergoing percutaneous coronary intervention (PCI). The studies indicate that cangrelor prior to PCI was not superior to clopidogrel in this setting, whereas ticagrelor prevented more deaths and ischemic events than clopidogrel in patients with ST-elevation myocardial infarction (STEMI) who underwent PCI. More... |
|
|
Rotavirus vaccination may lessen occurrence of gastroenteritis in small children
In the first year of a child’s life, immunization with a rotavirus vaccine (Rotarix, GlaxoSmithKline) may markedly lower incidence of severe virus gastroenteritis. Subsequently, the immunization may lead to notable reduction in diarrhea-triggered deaths in children under age 5, according to results of two studies published in the January 28 issue of the New England Journal of Medicine. More... |
|
|
|
| FDA Approvals |
| Pralatrexate injection (Folotyn): Folate analogue metabolic inhibitor approved for treatment of relapsed or refractory peripheral T-cell lymphoma |
| FDA actions in brief, January 2010 (Cymbalta, Zyprexa, Zyprexa Relprevv, Intelence, Kalbitor, Istodax, Geodon, Vagifem, Seroquel XR, Clonidine ER Suspension, Clonidine ER Tablets, Wilate) |
| First-time generic approvals, January 2010 |
|
|
|
|
|
| In the Pipeline |
| FDA Pipeline preview, January 2010 (Testosterone undecanoate injection, Telavancin, Ampligen, Doxepin, Everolimus, Aztreonam lysine, Erlotinib, TG4010, BSI-201, Midazolam, Aimspro, Motorgraft, BHR-100, Dextran sulfate) |
|
|
|
|
|
|
